Abstract:e22544 Background: Cancer is a leading cause of mortality and has been associated with an increasing prevalence of psychological disorders. Previous studies indicate that approximately 1 in 8 individuals diagnosed with lung cancer also experience symptoms of depression. Our study aimed to assess the disparities in the prevalence and association of Anxiety and Major depressive disorder (MDD) in lung cancer patients. Methods: Using the National Inpatient Sample 2017-2020, we identified lung cancer patients with regional and advanced metastatic disease. They were divided into two groups - with and without concomitant Anxiety and MDD. Baseline demographic characteristics were analyzed to assess disparities in prevalence, and multivariate logistic regression was used to evaluate the association of Anxiety and MDD in these patients. Results: A total of 461975 patients had lung cancer, and 25780(5%) had concurrent diagnoses of Anxiety and MDD. The anxiety + MDD group had 70% females and 30% males (p < 0.001).Females had an increased likelihood of MDD + Anxiety (OR = 2.36 (2.21-2.52); p 65: OR = 0.45(0.25-0.81); p = 0.008). Compared to the white population, patients of other races had a decreased likelihood of MDD + Anxiety (Black: OR = 0.41( 0.36-0.47), p < 0.001; Hispanic: OR = 0.65( 0.55-0.77), p < 0.001; Other races OR = 0.60(0.48-0.76), p < 0.001). Private insurance and patients without insurance were less likely to have MDD + Anxiety (OR = 0.74(0.67-0.81) and OR = 0.56(0.44-0.71), p < 0.001, respectively). Patients admitted to teaching and large hospitals had an increased likelihood of MDD + Anxiety compared to smaller and nonteaching hospitals (OR = 1.13(1.03-1.24), p = 0.006 and OR = 1.14(1.03-1.25), p = 0.007, respectively). Patients with Hyperlipidemia, Hypertension, COPD, and Obesity were more likely to have MDD + Anxiety (OR = 1.39(1.30-1.48), p < 0.001; OR = 1.11(1.03-1.18), p = 0.002; OR = 1.29(1.21-1.38), p < 0.001 and OR = 1.33(1.22-1.45), p < 0.001 respectively). In contrast, patients with Diabetes had a decreased likelihood of concomitant Anxiety + Depression (OR = 0.92(0.85-0.99), p = 0.04). Lung cancer patients with concurrent Anxiety + MDD had a higher total cost of hospitalization. (+$ 2611(66-5156); p = 0.04). Conclusions: Female lung cancer patients and white individuals had an increased risk of anxiety and depression. Patients with private insurance had decreased risk, and those admitted to larger and teaching hospitals had increased association with these psychological disorders. Devising comprehensive strategies to effectively control underlying psychiatric conditions is crucial for improving outcomes in lung cancer patients, aiming to enhance quality of life and prolong life expectancy.

A population-based analysis of the management of symptoms of depression among patients with stage IV non-small cell lung cancer (NSCLC) in Ontario, Canada

Depression in Patients With Lung Cancer: Prevalence and Risk Factors Derived From Quality-of-Life Data

Depression Symptoms among Patients with Lung Cancer and their Relations with Demographic Characteristics

Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment

Prevalence and risk factors of depression in patients with lung cancer: protocol for a systematic review and meta-analysis

Morbidity and associated factors of depressive disorder in patients with lung cancer

Enhancing Symptom Screening and Patient Education Among Patients with Metastatic Lung Cancer: a Qualitative Analysis

Clinical biopsychosocial risk factors for depression in lung cancer patients: a comprehensive analysis using data from the Lung Cancer Database Project.

Treatment of depression in people with lung cancer: A systematic review

Clinical Decision Support for Symptom Management in Lung Cancer Patients: A Group RCT

Chemotherapeutic Response and Prognosis among Lung Cancer Patients with and without Depression

Anxiety and Depression in Advanced and Metastatic Lung Cancer Patients-Correlations with Performance Status and Type of Treatment

Lung Cancer Stigma, Anxiety, Depression and Symptom Severity

Higher stress and symptom severity are associated with worse depressive symptom profiles in patients receiving chemotherapy

Gaps in Depression Symptom Management for Patients With Head and Neck Cancer

The Impact of Symptoms and Psychological Distress on Quality of Life in Early-Stage Lung Cancer Survivors

Identification of Distinct Symptom Profiles in Cancer Patients Using a Pre-Specified Symptom Cluster

Impact of Health-Related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice for Stage I Lung Cancer

Understanding veterans’ experiences with lung cancer and psychological distress: A multimethod approach.

Disparities in the prevalence of anxiety and major depressive disorder in patients with lung cancer and the associated risk factors: A retrospective analysis.